Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)
adalimumab, infliximab, ustekinumab, and vedolizumab were all effective in achieving clinical and endoscopic clinical outcomes in IBD in both UC and CD. The findings of this study suggest that the efficacy of biologics in a Middle Eastern population is similar to that in a Western population.
Authors
- Alaa Marei
- Fatema Alrashed (ORCID: https://orcid.org/0000-0003-4020-5978)
- Mohammad Shehab (ORCID: https://orcid.org/0000-0003-2084-3956)
- Wrood Alostad
- Israa Abdullah (ORCID: https://orcid.org/0000-0001-5262-7938)
- Ahmad Alfadhli
Institutions
- Mubarak Al Kabeer Hospital (KW)
- Kuwait University (KW)
- Dasman Diabetes Institute (KW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3389/fphar.2024.1388043
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.75